Detail Ancestry-based pharmacogenomics, adverse reactions and carbamazepine: is the FDA warning correct? (from The Pharmacogenomics Journal 2014, 14, 473-480) Bibliografi Author: Payne, P. W. Topik: Pharmacogenomics; FDA warning; Hepatitis - Drug new Bahasa: (EN )     Penerbit: Macmillan Publisher Ltd.     Tahun Terbit: 2014     Jenis: Article - diterbitkan di jurnal ilmiah internasional Fulltext: out (4).pdf (1.15MB; 1 download) [Informasi yang berkaitan dengan koleksi ini di internet] Abstract In an effort to prevent potentially fatal adverse reactions to carbamazepine, the US Food and Drug Administration (FDA) issued an alert in 2007 containing pharmacogenomic information, which is still in effect today. The alert states that carbamazepine-induced skin reactions are significantly more common in patients with the human leukocyte antigen (HLA)-B*1502 allele and that these people are almost exclusively from ‘broad areas of Asia, including South Asian Indians.’ This study reviews the medical evidence relied upon by the FDA and finds that the alert does not accurately reflect the medical evidence relied upon in 2007 or evidence that has been generated over the last 5 years since the label was created. The FDA drug labeling should be modified to reflect current medical evidence. [hepatitis - drug new] Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Lihat Sejarah Pengadaan  Konversi Metadata   Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved